NanoViricides says Phase IIa Ebola trial of NV-387 oral gummies progresses well

• NanoViricides flagged steady progress in its Phase IIA trial of NV-387 oral gummies for Bundibugyo Ebola in the DRC.
• No results have been presented yet; a safety and tolerability update is expected once Phase IIA ends and investigators complete a report.
• The study aims to identify a workable dosing regimen in very ill patients, with treatment stopped when testing shows no detectable virus.
• The design is not intended to deliver statistically powered efficacy results, though management expects any strong benefit could still be apparent.
• A selected regimen would move into a larger randomized, controlled Phase IIB study to evaluate effectiveness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610130845ACCESSWRNAPR_____1236191) on October 13, 2026, and is solely responsible for the information contained therein.